ABOUT THIS CONFERENCE
G protein-coupled receptors (GPCRs) are among the most common types of molecules that medicines work upon. These receptors continue to be a focus of new drug discovery not only due to their cell surface location which makes them accessible to ingested therapies, but also because of the role they play in so many cell types as the 'sensor or transmitter' of extra-cellular chemical signals into messages that result in cellular change.
Two back-to-back GPCR conferences will cover the challenges faced with the industry's current paradigm of target-driven discovery.
GPCR-Based Drug Discovery, the first day and a half conference of our back-to-back GPCR conferences, will cover screening and discovery strategies for compounds, including allosteric modulators, acting on GPCRs. A few talks will also be devoted to the findings and impact of the slew of recent crystal structures of medically relevant GPCRs that have been elucidated. New assays to uncover or methods to direct ligand-biased signaling will be another focus of the conference.
SUGGESTED EVENT PACKAGE:
September 23: Practical Aspects of Structure-Based Drug Discovery with GPCRs Short Course
September 23: Allosteric Modulators of GPCRs Short Course
September 24 - 25: GPCR-Based Drug Discovery Conference
September 25 - 26: GPCR-Targeted Therapies Conference
Scientific Advisory Board:
Andrew Alt, Ph.D., Senior Research Investigator II, Lead Discovery, Bristol-Myers Squibb Co.
Structure of FSH and Receptor Ectodomain Complex: Relevance to the Discovery of Small Molecule Allosteric Modulators
Xuliang Jiang, Ph.D., Associate Director, Structural Biology and Computational Chemistry, EMD Serono
Molecular Signatures of GPCRs
Christopher Tate, Ph.D., Professor, Laboratory of Molecular Biology, MRC, Cambridge, United Kingdom
FEATURED PRESENTATION
Roger K. Sunahara, Associate Professor, Pharmacology, University of Michigan Medical School
Discovery of b-arrestin-Biased Agonists of Dopamine D2 receptors
Kyle Butler, Ph.D., Post-Doctoral Fellow, Laboratory of Jian Jin, Division of Chemical Biology and Medicinal Chemistry, The University of North Carolina at Chapel Hill
GPCR Biased Ligands as Improved Therapeutics: Promise and Progress
Jonathan Violin, Ph.D., Director, Biology, Trevena, Inc.
Label-Free Assays to Probe Ligand-Biased Signaling
Hong Xin, Ph.D., Senior Scientist, Lead Generation, Johnson & Johnson Pharmaceutical R&D
Talk Title to be Announced
Andrew Alt, Ph.D., Senior Research Investigator II, Lead Discovery, Bristol-Myers Squibb Co.
Something Old, Something New, Something Borrowed, Something Glu: Lessons Learned in the Design of Ligands for Metabotropic Glutamate Receptors
Dario Doller, Ph.D., Director, Discovery Chemistry & DMPK, Lundbeck Research USA
The "No Ligand Depletion" Assumption is Unnecessary and Can Be Misleading
Gilles Gnacadja, Ph.D., Principal Analyst, System Informatics, Amgen
Additional Sponsored Presentation
Speaker to be Announced